Abstract: The invention relates to novel transdermally applicable pharmaceutical preparations containing glycosides; a solvent selected from the group consisting of ethoxylated sterols and ethoxylated alcohols with 12 to 30 carbon atoms; and lipophilic ointment base.

Abstract: The invention relates to novel, transdermally applicable pharmaceutical preparations including sterolines or spiroketalines, a solvent selected from the group consisting of ethoxylated sterols and C12-C30 alcohols, and lipophilic ointment base. Methods of treatment using same.

Abstract: As a process for preparing a compound of the formula ##STR1## in which both Rs are H or --OH comprising the steps: a. of treating the ethyl ester of caffeic acid with a trialkylsilyl chloride at ambient conditions in equimolar proportions in the presence of a base;b. of reduction of the resulting product with an aluminium hydride reagent at sub-zero temperature and equimolar proportions to yield the corresponding allylic alcohol;c. of halogenation of this allylic alcohol with thionyl chloride or a phosphorus trihalide to yield the corresponding allyl halide;d. of coupling this allyl halide with the silyl ether of compound of the formula ##STR2## in refluxing ether solutions; and e. of hydrolysis of this coupled product with tetra alkyl ammonium flouride at ambient conditions and of equimolar proportions.

Abstract: The invention relates to the use of phytosteryl glycoside or their esters for the treatment of conditions caused by increased endogenous epoxycholesterol levels in human organs and organ fluids especially those with glandular function; and to compositions and method for treating such conditions.

Abstract: The present invention provides a pharmaceutical composition, primarily for the treatment of inflammatory conditions, including benign prostata hypertrophy, the composition containing a spiroketalin such as diosgenyl-.beta.-D-glycoside or hecogenyl-.beta.-D-glycoside. A unit dosage form is provided which contains between 0,3 and 0,75 mgm of the spiroketalin.

Abstract: Medicaments are prepared having activity as prostaglandin synthetase inhibitor comprising certain sterol glycosides, a fatty acid ester thereof or a spiroketal-steroid glucoside or fatty acid ester thereof in an amount sufficient to inhibit a prostaglandin synthetase.

Abstract: The invention is concerned with new chemical compounds being the hemiesters of steryl glycosides, methods of preparing these hemiesters, and pharmaceutically, particularly anti-inflammatory, compositions containing the new hemiesters.

Abstract: Plant material derived from the family Hypoxidaceae is heated at a temperature of at least 60.degree. C. for a sufficient period to ensure enzyme destruction and is then extracted at a temperature of 0.degree.-30.degree. C. with aqueous alcohol containing 30-75 volume percent ethanol for about 1 to 15 days to obtain a pharmaceutically active material.

Abstract: Sterol glycosides and esters thereof with monocarboxylic acids of natural or synthetic origin are used to combat human and animal illness in dosages of not over 10 mg per day.

Abstract: Plant material derived from the family Hypoxidaceae is heated at a temperature of at least 60.degree. C. for a sufficient period to ensure enzyme destruction and is then extracted at a temperature of 0.degree.-30.degree. C. with aqueous alcohol containing 30-75 volume percent ethanol for about 1 to 15 days to obtain a pharmaceutically active material.